Clinical trial
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or…
NCT00096044 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00096044 |
|---|---|
| Title | Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | CC-5013 Alone or in Combination With Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | Celgene Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | rituximab, lenalidomide |
| Enrollment | 45 |
| Start date | Mar 1, 2004 |
| Primary completion | Jun 1, 2015 |
| Completion | Jun 1, 2015 |
| First posted | Nov 9, 2004 |
| Last update posted | Jul 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: